Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Rhea-AI Summary
Viatris (Nasdaq: VTRS) announced six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (MR-100A-01) will be presented at the ACOG 2026 Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Presentations include positive Phase 3 efficacy and safety results, adhesion and pharmacokinetic data, and cycle control findings. Sessions and times for six electronic poster presentations and an educational symposium supported by Viatris are listed; Viatris will be at booth #223.
Positive
- None.
Negative
- None.
News Market Reaction – VTRS
On the day this news was published, VTRS gained 0.67%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Ahead of this news, VTRS slipped 0.2% while key peers were mixed: RDY -1.16%, TEVA -2.62%, UTHR -0.54%, NBIX -0.28%, and ELAN +1.96%. No peers appeared in the momentum scanner and there were no same-day peer headlines, indicating this looked stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Earnings date notice | Neutral | +2.7% | Announcement of timing and webcast details for Q1 2026 results. |
| Apr 10 | Medical meeting data | Positive | -1.0% | Multiple ophthalmology abstracts and educational symposium at ASCRS. |
| Mar 23 | Regulatory approval | Positive | +0.7% | MHLW approval of Effexor SR for GAD in Japan supported by Phase 3 data. |
| Mar 19 | Long-term guidance | Positive | -1.8% | 2030 revenue, EBITDA, EPS CAGR targets and cash deployment framework. |
| Feb 26 | Earnings release | Neutral | -5.2% | Q4/FY 2025 results, 2026 guidance, cost savings and workforce reduction. |
Recent news has produced mixed reactions: positive strategic and clinical updates sometimes saw modest gains, while earnings and long-term targets occasionally coincided with declines.
Over the last six months, Viatris has alternated between strategic, financial, and clinical milestones. The company reported Q4/FY 2025 results with $14.3B in revenues and significant cost-savings plans, then outlined growth targets through 2030. It secured Japanese approval for Effexor in GAD and highlighted multiple Phase 3 readouts and pipeline assets in filings and ophthalmology meeting presentations. The current contraceptive patch Phase 3 and adhesion/pharmacokinetic data continue this theme of leveraging late-stage and lifecycle assets across therapeutic areas.
Market Pulse Summary
This announcement highlights expanded clinical and pharmacokinetic data for Viatris’ investigational low-dose estrogen combined hormonal contraceptive patch, including Phase 3 efficacy, safety, adhesion, and cycle control results across six abstracts at ACOG 2026. It reinforces the company’s focus on non-oral contraceptive options and medical education through an independent PRIME symposium. In context of recent Phase 3 readouts and regulatory wins, investors may watch future regulatory filings, additional trial outcomes, and how this asset integrates into Viatris’ broader women’s health strategy.
Key Terms
combined hormonal contraceptive medical
transdermal medical
pharmacokinetics medical
AI-generated analysis. Not financial advice.
The presentations will include positive results from the previously announced Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of the Company's investigational low-dose estrogen CHC weekly patch. In addition, presentations will highlight new data on the patch's adhesion profile under normal and under extreme conditions, as well as pharmacokinetic data and data on cycle control.
All accepted scientific abstracts are available on the ACOG Annual Meeting website.
Full List of Viatris Presentations at 2026 ACOG ACSM:
Abstract | Abstract Details |
Abstract No. E26 Patch Adhesion Performance of a Low-Dose | Electronic Poster Industry ePoster Session E (IEP05) Saturday, May 2 8–9 a.m. EDT |
Abstract No. E27 | Electronic Poster Industry ePoster Session E (IEP05) Saturday, May 2 8–9 a.m. EDT |
Abstract No. G19 Contraceptive Efficacy of MR-100A-01 in Women of | Electronic Poster Industry ePoster Session G (IEP07) Saturday, May 2 1:30–2:30 p.m. EDT |
Abstract No. G20 MR-100A-01 Weekly Transdermal Contraceptive | Electronic Poster Industry ePoster Session G (IEP07) Saturday, May 2 1:30–2:30 p.m. EDT |
Abstract No. G21 MR-100A-01 Weekly Transdermal Contraceptive | Electronic Poster Industry ePoster Session G (IEP07) Saturday, May 2 1:30–2:30 p.m. EDT |
Abstract No. G22 | Electronic Poster Industry ePoster Session G (IEP07) Saturday, May 2 1:30–2:30 p.m. EDT |
In complement to its scientific program, and to further foster peer-to-peer exchange and support clinicians in the evolving landscape of non-oral contraceptive options, Viatris provided an independent educational grant for the following educational symposium hosted by PRIME®, a nationally recognized continuing medical education platform:
- Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities
- Friday, May 1
- 6–7:30 p.m. ET
- Marriott Marquis
Washington, D.C. , Salon 5 (Meeting Level 2)
More information on the data presentations and symposium can be found on the ACOG ACSM website here, and Viatris can be found at booth #223.
About Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch
The investigational treatment is a once-weekly transdermal contraceptive patch being developed for women of childbearing potential with a BMI below 30 kg/m² who are appropriate candidates for combined hormonal contraception (CHC) and who prefer a non-invasive, reversible option with a lower estrogen dose.
The
The investigational low-dose estrogen CHC weekly patch aims to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best-in-class adhesion performance. This investigational treatment option builds upon the Company's established capability in transdermal drug delivery and represents a lifecycle advancement of the contraceptive patch, Xulane® (norelgestromin and ethinyl estradiol transdermal system) 150/35 mcg per day.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements about the investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch; the outcomes of clinical trials; FDA has accepted for review the NDA for the Company's investigational low-dose estrogen CHC weekly patch; the NDA is accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a target action date (PDUFA) of July 30, 2026; the NDA is supported by results from a multicenter, open-label, single-arm, Phase 3 study (NCT05139121), which evaluated the safety and contraceptive efficacy of the investigational low-dose estrogen CHC weekly patch and which demonstrated a favorable efficacy and safety profile and strong patch adhesion performance; the investigational low-dose estrogen CHC weekly patch aims to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best-in-class adhesion performance; this investigational treatment option builds upon the Company's established capability in transdermal drug delivery and represents a lifecycle advancement of the contraceptive patch, Xulane® (norelgestromin and ethinyl estradiol transdermal system) 150/35 mcg per day. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-several-data-presentations-on-investigational-low-dose-estrogen-combined-hormonal-contraceptive-weekly-patch-at-the-2026-american-college-of-obstetricians-and-gynecologists-annual-clinical--scientific-meeting-302759662.html
SOURCE Viatris Inc.